P&G Chooses Merck's Consumer Health Business In $4.2bn Deal
This article was originally published in The Rose Sheet
Executive Summary
The global health, personal and household care marketer's agreement with the German firm that will bring under its roof nutritional products including Cebion vitamin C, Neurobion B complex vitamins, Femibion folic acid, Ominibionta 3 All Day Energy and Sangobion iron supplements.
You may also be interested in...
P&G Could Be Last Suitor Standing For Pfizer's Consumer Health Business
A spin-off still is an option for Pfizer, as is continuing to operate the unit as it currently does. But P&G's apparent interest and dearth of other OTC business buyers changes the outlook for both companies.
GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes
Reckitt and GSK withdraw from negotiating on potential deals for with Pfizer's consumer business, leaving slim chances Pfizer will receive an acceptable offer from other drug firms mentioned as potential suitors for the business, which it has valued at around $20bn. A spin-off could move to the fore.